Insider Transactions in Q4 2021 at Quanterix Corp (QTRX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-6.68%
|
$66,680
$40.71 P/Share
|
|
Dec 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
350
-0.54%
|
$14,000
$40.63 P/Share
|
|
Dec 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
353
-0.46%
|
$14,120
$40.63 P/Share
|
|
Dec 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
147
-0.31%
|
$5,880
$40.63 P/Share
|
|
Dec 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,710
-0.21%
|
$148,400
$40.63 P/Share
|
|
Nov 19
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-6.26%
|
$75,015
$45.54 P/Share
|
|
Nov 18
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
9,318
+7.48%
|
-
|
|
Nov 18
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
290,250
-100.0%
|
-
|
|
Nov 16
2021
|
Keith Crandell |
BUY
Other acquisition or disposition
|
Direct |
9,952
+8.59%
|
-
|
|
Nov 16
2021
|
Keith Crandell |
SELL
Other acquisition or disposition
|
Indirect |
310,000
-51.65%
|
-
|
|
Nov 10
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.18%
|
$275,000
$55.13 P/Share
|
|
Nov 05
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
8,535
-9.08%
|
$486,495
$57.82 P/Share
|
|
Nov 05
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
BUY
Exercise of conversion of derivative security
|
Direct |
10,718
+18.5%
|
$203,642
$19.12 P/Share
|
|
Nov 04
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
1
-0.0%
|
$57
$57.0 P/Share
|
|
Nov 02
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
331
-0.5%
|
$17,212
$52.77 P/Share
|
|
Nov 02
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,505
-0.19%
|
$182,260
$52.77 P/Share
|
|
Nov 02
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
333
-0.45%
|
$17,316
$52.77 P/Share
|
|
Nov 02
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
139
-0.3%
|
$7,228
$52.77 P/Share
|
|
Oct 22
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.18%
|
$250,000
$50.94 P/Share
|
|
Oct 15
2021
|
David C. Duffy SVP R&D and CTO |
SELL
Open market or private sale
|
Direct |
1,667
-5.89%
|
$85,017
$51.47 P/Share
|
|
Oct 01
2021
|
Paul M Meister |
BUY
Grant, award, or other acquisition
|
Direct |
269
+1.89%
|
$13,719
$51.18 P/Share
|
|
Oct 01
2021
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
354
+2.25%
|
$18,054
$51.18 P/Share
|
|
Oct 01
2021
|
Sarah E. Hlavinka |
BUY
Grant, award, or other acquisition
|
Direct |
232
+1.91%
|
$11,832
$51.18 P/Share
|
|
Oct 01
2021
|
Mark T. Roskey SVP, Strategic Partnerships |
SELL
Open market or private sale
|
Direct |
143
-0.6%
|
$7,293
$51.2 P/Share
|
|
Oct 01
2021
|
Dawn Mattoon Sr. VP, Diagnostics |
SELL
Open market or private sale
|
Direct |
342
-0.92%
|
$17,442
$51.2 P/Share
|
|
Oct 01
2021
|
John J Fry General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
340
-1.02%
|
$17,340
$51.2 P/Share
|
|
Oct 01
2021
|
Keith Crandell |
BUY
Grant, award, or other acquisition
|
Direct |
254
+0.26%
|
$12,954
$51.18 P/Share
|
|
Oct 01
2021
|
E Kevin Hrusovsky Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,594
-0.39%
|
$183,294
$51.2 P/Share
|